Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

Luca Saverio Belli, Marina Berenguer, Paolo Angelo Cortesi, Mario Strazzabosco, Susanne Rasoul Rockenschaub, Silvia Martini, Cristina Morelli, Francesca Donato, Riccardo Volpes, Georges Philippe Pageaux, Audrey Coilly, Stefano Fagiuoli, Giuliana Amaddeo, Giovanni Perricone, Carmen Vinaixa, Gabriela Berlakovich, Rita Facchetti, Wojciech Polak, Paolo Muiesan, Christophe Duvoux

Research output: Contribution to journalArticlepeer-review


Background & Aims: All oral direct acting antivirals (DAA) have been shown to improve the liver function of patients with decompensated cirrhosis but it is presently unknown whether this clinical improvement may lead to the delisting of some patients. The aim of this study was to assess if and which patients can be first inactivated due to clinically improvement and subsequently delisted in a real life setting. Methods: 103 consecutive listed patients without hepatocellular carcinoma were treated with different DAA combinations in 11 European centres between February 2014 and February 2015. Results: The cumulative incidence of inactivated and delisted patients by competing risk analysis was 15.5% and 0% at 24. weeks, 27.6% and 10.3% at 48. weeks, 33.3% and 19.2% at 60. weeks. The 34 patients who were inactivated showed a median improvement of 3.4 points for MELD (delta MELD, . p . 20:HR = 0.042; . p .

Original languageEnglish
Pages (from-to)524-531
Number of pages8
JournalJournal of Hepatology
Issue number3
Publication statusPublished - 2016


  • Cirrhosis
  • Delisting
  • Direct acting antivirals
  • HCV
  • Liver transplantation

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study'. Together they form a unique fingerprint.

Cite this